… primary end points in Japanese patients compared against results previously reported for
the ITT population. We also evaluate the secondary end points in the Japanese subpopulation. …

… cell lung cancer (NSCLC), despite initial response to EGFR-tyrosine kinase inhibitors (TKIs).
In Japan, … method used for re-biopsy to identify patients eligible for treatment. We aimed to …

… common in patients with lung cancer. Although … patients. In this study, we evaluated the
efficacy of gefitinib alone without radiation therapy for the treatment of patients with BM from lung …

… in females, never smokers, patients of Asian ethnicity, and those … of lung adenocarcinomas
from Japanese patients harbored … in lung cancers, 17 and about 10% of NSCLCs of Japanese …

… in Japanese patients has shown promise, the authors evaluated EGFR mutations and gene
amplification in biopsy specimens from Japanese patients with nonsmall cell lung cancer (…

… Patients and methods This open-label, phase III study randomized 490 Japanese patients
to gefitinib (250 mg/day) or docetaxel (60 mg/m 2 /3 weeks), with survival as the primary …

… generic questionnaire for Japanese cancer patients undergoing … in Japanese patients with
advanced non-small-cell lung cancer (… research on Japanese patients with advanced NSCLC. …

… lung disease (ILD) in Japanese patients with non-small-cell lung cancer who received
gefitinib. This study reports the association between gefitinib exposure and the occurrence of ILD. …

… illness perceptions in Dutch and Japanese patients with non-small-cell lung cancer, thereby
extending the … 24 Dutch and 22 Japanese patients with non-small-cell lung cancer filled out …

… intervention in NSCLC patients with pleural carcinomatosis in Japan. … Japanese Joint
Committee of Lung Cancer Registry conducted a nationwide registration of lung cancer patients …